Evidence map›Paper›PMID 41969323›Full record

ReviewCurrent urology2026

Interleukin-11: A pivotal player and potential therapeutic target in prostate cancer.

Jinghua Zhong, Xiaolu Duan, Ziyi Wei, Wei Zhu, Zhijian Zhao, Guohua Zeng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jinghua ZhongDepartment of Urology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Xiaolu DuanDepartment of Urology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Ziyi WeiDepartment of Urology, Yuebei People's Hospital, Shantou University Medical College, Shaoguan, China.
Wei ZhuDepartment of Urology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Zhijian ZhaoDepartment of Urology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Guohua ZengDepartment of Urology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin-11 (IL-11), a pleiotropic cytokine belonging to the interleukin-6 (IL-6) family, is implicated in the initiation and progression of various malignancies. Recent studies revealed that IL-11 plays multifaceted roles in prostate cancer, contributing to tumor cell proliferation, castration resistance, bone metastasis, and chemotherapeutic resistance. Interleukin-11 has emerged as a promising target for both diagnostic and therapeutic strategies. This review outlines the molecular structure and biological functions of IL-11; summarizes its role in early diagnosis, prognostic evaluation, tumor progression, and therapeutic intervention for prostate cancer; and explores its potential as a novel therapeutic target.

Indexed as

Bone metastasisChemotherapeutic resistanceDiagnosisInterleukin-11Prostate cancerTarget therapy

Identifiers

PMID41969323
PMCPMC13068482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.